Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

BACKGROUND: Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors. This publication describes the safety profile of onartuzumab in patients with solid tumors usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morley, Roland, Cardenas, Alison, Hawkins, Peter, Suzuki, Yasuyo, Paton, Virginia, Phan, See-Chun, Merchant, Mark, Hsu, Jessie, Yu, Wei, Xia, Qi, Koralek, Daniel, Luhn, Patricia, Aldairy, Wassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596876/
https://www.ncbi.nlm.nih.gov/pubmed/26445503
http://dx.doi.org/10.1371/journal.pone.0139679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596876/
https://www.ncbi.nlm.nih.gov/pubmed/26445503
http://dx.doi.org/10.1371/journal.pone.0139679

Ejemplares similares